

DRUG REGIMEN

Imatinib

Indication for use

Unresectable and/or metastatic malignant gastrointestinal tumour (GIST)

Regimen

400mg orally daily continuously until disease progression

Investigation prior to initiating treatment

Biopsy proven GIST
FBC, U&E'S, LFT's

Cautions

Monitor closely if deranged LFT's

Investigations and consultations prior to each cycle

Consultations weekly for one month, then monthly for 2 months then every 3 months
FBC and LFT's checked at each visit
Monitor weight
Monitor disease response every 3 months (CT scan)

Acceptable levels for treatment to proceed (if outside these levels defer one week or contact consultant)

Defer if bilirubin is >3x ULN until it is back to <1.5x ULN
Defer if AST or ALT are >5x ULN until back to <2.5x ULN
Defer and consider dose reduction if severe neutropenia or thrombocytopenia (discuss with consultant if Neuts<1.0 or platelets<100)

Side Effects

Neutropenia, thrombocytopenia and anaemia
Diarrhoea, nausea, abdominal pain, rash
Fluid retention and oedema

Dose Modification Criteria

As above

Specific Information on Administration

To be taken with a meal and a large glass of water

THIS PROTOCOL HAS BEEN DIRECTED BY DR YOUNG, DESIGNATED LEAD CLINICIAN FOR UPPER GI CANCER

RESPONSIBILITY FOR THIS PROTOCOL LIES WITH THE HEAD OF SERVICE

DATE **October 2015**
REVIEW **October 2017**
VERSION **6**